ABVC
Income statement / Annual
Last year (2023), ABVC BioPharma, Inc.'s total revenue was $152,430.00,
a decrease of 84.28% from the previous year.
In 2023, ABVC BioPharma, Inc.'s net income was -$10.52 M.
See ABVC BioPharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
09/30/2016 |
09/30/2015 |
09/30/2014 |
Operating Revenue |
$152,430.00
|
$969,783.00
|
$355,797.00
|
$483,045.00
|
$701,719.00
|
$6,956.00
|
$3,196.00
|
$32.00
|
$3,360.00
|
$0.00
|
Cost of Revenue |
$302,037.00 |
$286,415.00 |
$5,086.00 |
$18,716.00 |
$20,137.00 |
$185,280.00 |
$2,249.00 |
$32.00 |
$521.00 |
$0.00 |
Gross Profit |
-$149,607.00 |
$683,368.00 |
$350,711.00 |
$464,329.00 |
$681,582.00 |
-$178,324.00 |
$947.00 |
$0.00 |
$2,839.00 |
$0.00 |
Gross Profit Ratio |
-0.98 |
0.7 |
0.99 |
0.96 |
0.97 |
-25.64 |
0.3 |
0 |
0.84 |
0 |
Research and Development
Expenses |
$1.06 M
|
$2.69 M
|
$1.00 M
|
$549,658.00
|
$1.05 M
|
$669,668.00
|
$256,682.00
|
$10.00 M
|
$0.00
|
$0.00
|
General & Administrative
Expenses |
$7.00 M
|
$13.10 M
|
$11.05 M
|
$8.42 M
|
$3.09 M
|
$723,948.00
|
$1.74 M
|
$4.50 M
|
$0.00
|
$0.00
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$695,148.00
|
$1.74 M
|
$4.50 M
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$7.00 M
|
$13.10 M
|
$11.05 M
|
$8.42 M
|
$3.09 M
|
$723,948.00
|
$1.74 M
|
$4.50 M
|
$35,120.00
|
$0.00
|
Other Expenses |
$0.00 |
$83,001.00 |
-$360,898.00 |
$199,641.00 |
$116,846.00 |
$0.00 |
$63,388.00 |
$0.00 |
$35,120.00 |
$70.00 |
Operating Expenses |
$8.07 M |
$15.80 M |
$11.70 M |
$8.97 M |
$4.14 M |
$1.39 M |
$1.99 M |
$4.50 M |
$35,120.00 |
$70.00 |
Cost And Expenses |
$8.37 M |
$16.08 M |
$11.70 M |
$8.99 M |
$4.16 M |
$1.39 M |
$1.99 M |
$4.50 M |
$35,641.00 |
$70.00 |
Interest Income |
$185,481.00 |
$187,817.00 |
$43,196.00 |
$71,045.00 |
$23,344.00 |
$93.00 |
$7,207.00 |
$361.00 |
$0.00 |
$0.00 |
Interest Expense |
$2.49 M |
$293,968.00 |
$227,210.00 |
$405,032.00 |
$482,014.00 |
$155,930.00 |
$222,060.00 |
$10,170.00 |
$0.00 |
$0.00 |
Depreciation &
Amortization |
$28,531.00
|
$23,799.00
|
$11,993.00
|
$37,142.00
|
$55,086.00
|
$43,610.00
|
$43,996.00
|
$11.00 M
|
$1.89 M
|
$0.00
|
EBITDA |
-$8.13 M
|
-$15.20 M
|
-$10.97 M
|
-$10.37 M
|
-$3.47 M
|
-$2.74 M
|
-$4.00 M
|
$561.00
|
-$32,281.00
|
-$70.00
|
EBITDA Ratio |
-53.35 |
-15.28 |
-31.28 |
-16.97 |
-4.65 |
-200.33 |
-587.32 |
-140529.19 |
-9.61 |
0 |
Operating Income Ratio
|
-53.9
|
-15.59
|
-31.89
|
-17.61
|
-4.93
|
-200.35
|
-623.17
|
-140540.47
|
-9.61
|
0
|
Total Other
Income/Expenses Net |
-$2.44 M
|
-$400,184.00
|
$495,141.00
|
-$2.31 M
|
-$551,503.00
|
-$1.31 M
|
-$3.03 M
|
-$9,668.00
|
$0.00
|
$0.00
|
Income Before Tax |
-$10.65 M |
-$15.51 M |
-$11.21 M |
-$10.81 M |
-$4.01 M |
-$4.10 M |
-$7.03 M |
-$4.51 M |
-$32,281.00 |
-$70.00 |
Income Before Tax Ratio
|
-69.9
|
-16
|
-31.51
|
-22.39
|
-5.71
|
-589.34
|
-2199.72
|
-140842.59
|
-9.61
|
0
|
Income Tax Expense |
$256,006.00 |
$797,778.00 |
$825,024.00 |
-$220,352.00 |
-$77,041.00 |
$1,850.00 |
-$360,395.00 |
$836.00 |
-$1.89 M |
$0.00 |
Net Income |
-$10.52 M |
-$16.31 M |
-$12.04 M |
-$10.59 M |
-$3.93 M |
-$4.10 M |
-$5.05 M |
-$4.51 M |
-$32,281.00 |
-$70.00 |
Net Income Ratio |
-68.99 |
-16.82 |
-33.83 |
-21.93 |
-5.61 |
-589.61 |
-1579.56 |
-140868.72 |
-9.61 |
0 |
EPS |
-2.43 |
-5.15 |
-4.8 |
-5.37 |
-2.25 |
-3.53 |
-29.58 |
-4.18 |
-0.37 |
-0.37 |
EPS Diluted |
-2.43 |
-5.15 |
-4.8 |
-5.37 |
-2.25 |
-3.45 |
-29.58 |
-4.18 |
-0.37 |
-0.37 |
Weighted Average Shares
Out |
$4.34 M
|
$3.17 M
|
$2.51 M
|
$1.97 M
|
$1.75 M
|
$1.16 M
|
$170,669.00
|
$1.08 M
|
$87,266.00
|
$190.00
|
Weighted Average Shares
Out Diluted |
$4.34 M
|
$3.17 M
|
$2.51 M
|
$1.97 M
|
$1.75 M
|
$1.19 M
|
$170,669.00
|
$1.08 M
|
$87,266.00
|
$190.00
|
Link |
|
|
|
|
|
|
|
|
|
|